ITT analysis showed sufferers treated with masitinib experienced a statistically significant change from baseline in ACQ7 total score , while the placebo group showed simply no significant change statistically. This phase 3 study is financed.. AB Research initiates recruitment in masitinib stage 3 study in severe persistent asthma AB Research SA , a pharmaceutical business specialising in the study, advancement and commercialisation of protein kinase inhibitors , announced today the recruitment of the first patient in the stage 3 research evaluating masitinib in severe persistent asthma. That is an international, multicenter, randomised, double-blind, placebo-controlled, 2-parallel organizations, Phase 3 study to compare the efficacy and the protection of masitinib at 6 mg/kg/time versus placebo in the treating patients with Severe Persistent Asthma treated with oral corticosteroids.There was no significant between-group difference in the primary composite cardiovascular end result or in the secondary composite cardiovascular outcome . Outcomes from all sensitivity analyses had been consistent with the findings in the main analyses. Various other Secondary Outcomes There was no significant difference in the rate of hospitalization for heart failure, which was reported in 228 patients in the sitagliptin group and 229 in the placebo group .